Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines

Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones

(2012) Paul A. Dutchak et al.   CELL

Plasma Levels of Fetuin-A and Hepatic Enzymes and Risk of Type 2 Diabetes in Women in the U.S.

(2012) Qi Sun et al.   DIABETES

Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance

(2012) C. Bianchi et al.   DIABETES CARE

Adiponectin Trajectories Before Type 2 Diabetes Diagnosis: Whitehall II study

(2012) A. G. Tabak et al.   DIABETES CARE

Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

(2012) C. Ortiz-Lopez et al.   DIABETES CARE

Dorothy Hodgkin Lecture 2012* Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management

(2012) C. D. Byrne   DIABETIC MEDICINE

TNF-α Represses β-Klotho Expression and Impairs FGF21 Action in Adipose Cells: Involvement of JNK1 in the FGF21 Pathway

(2012) Julieta Díaz-Delfín et al.   ENDOCRINOLOGY

How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease

(2012) Mariana V. Machado et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Metformin Stimulates FGF21 Expression in Primary Hepatocytes

(2012) Eva B. Nygaard et al.   Experimental Diabetes Research

Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes

(2012) Chih-Hao Wang et al.   FEBS Journal

NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications

(2012) Geoffrey C. Farrell et al.   Gut and Liver

Effect of Nonalcoholic Fatty Liver Disease on the Development of Type 2 Diabetes in Nonobese, Nondiabetic Korean Men

(2012) Chang Wook Chon et al.   Gut and Liver

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Metformin Regulates Glucose Transporter 4 (GLUT4) Translocation through AMP-activated Protein Kinase (AMPK)-mediated Cbl/CAP Signaling in 3T3-L1 Preadipocyte Cells

(2012) Jung Ok Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Relationship of Serum Fibroblast Growth Factor 21 with Abnormal Glucose Metabolism and Insulin Resistance: The Baltimore Longitudinal Study of Aging

(2012) Richard D. Semba et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice

(2012) Ruby L.C. Hoo et al.   JOURNAL OF HEPATOLOGY

Combined Use of Serum Adiponectin and Tumor Necrosis Factor-Alpha Receptor 2 Levels Was Comparable to 2-Hour Post-Load Glucose in Diabetes Prediction

(2012) Yu-Cho Woo et al.   PLoS One

Liraglutide Increases FGF-21 Activity and Insulin Sensitivity in High Fat Diet and Adiponectin Knockdown Induced Insulin Resistance

(2012) Mengliu Yang et al.   PLoS One

Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose

(2011) Ralph A. DeFronzo et al.   AMERICAN JOURNAL OF CARDIOLOGY

Thiazolidinediones Are Potent Inducers of Fibroblast Growth Factor 21 Expression in the Liver

(2011) Katsutaka Oishi et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Selective Inactivation of c-Jun NH2-Terminal Kinase in Adipose Tissue Protects Against Diet-Induced Obesity and Improves Insulin Sensitivity in Both Liver and Skeletal Muscle in Mice

(2011) X. Zhang et al.   DIABETES

High Plasma Level of Fibroblast Growth Factor 21 Is an Independent Predictor of Type 2 Diabetes: A 5.4-year population-based prospective study in Chinese subjects

(2011) C. Chen et al.   DIABETES CARE

AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study

(2011) J. G. Boyle et al.   DIABETOLOGIA

Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus

(2011) Tomoyuki Iwasaki et al.   HEPATO-GASTROENTEROLOGY

Growth Hormone Induces Hepatic Production of Fibroblast Growth Factor 21 through a Mechanism Dependent on Lipolysis in Adipocytes

(2011) Wei Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction

(2011) Paulina Pettinelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Natural course of nonalcoholic fatty liver disease in southern China: A prospective cohort study

(2011) Yong Jian ZHOU et al.   Journal of Digestive Diseases

Pioglitazone in the treatment of NASH: the role of adiponectin

(2010) A. Gastaldelli et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

Adipocyte Fatty Acid-binding Protein Modulates Inflammatory Responses in Macrophages through a Positive Feedback Loop Involving c-Jun NH2-terminal Kinases and Activator Protein-1

(2010) Xiaoyan Hui et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Elevated Fetuin-A Concentrations in Morbid Obesity Decrease after Dramatic Weight Loss

(2010) Johanna Maria Brix et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin

(2010) Mingyan Zhou et al.   JOURNAL OF HEPATOLOGY

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

(2010) Huating Li et al.   JOURNAL OF HEPATOLOGY

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

(2010) Shani Ben-Shlomo et al.   JOURNAL OF HEPATOLOGY

Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects

(2010) Young-Choon Kim et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis

(2010) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1

(2010) Masato Iwabu et al.   NATURE

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications

(2009) Yu Wang et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway

(2009) Motoharu Awazawa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance

(2009) A. O. Chavez et al.   DIABETES CARE

Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis

(2009) Michael Kremer et al.   HEPATOLOGY

Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease

(2009) Kerry-Lee Milner et al.   HEPATOLOGY

Low Serum Adiponectin Predicts 10-Year Risk of Type 2 Diabetes and HbA1c Independently of Obesity, Lipids, and Inflammation: Whitehall II Study

(2009) A. G. Tabák et al.   HORMONE AND METABOLIC RESEARCH

Low Serum Adiponectin Levels Are Predictive of Advanced Hepatic Fibrosis in Patients With NAFLD

(2009) Savvoula Savvidou et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease

(2009) Jung Won Yun et al.   LIVER INTERNATIONAL

Final results of a long-term, clinical follow-up in fatty liver patients

(2009) Sanne Dam-Larsen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal

(2009) Naim Alkhouri et al.   Expert Review of Gastroenterology & Hepatology

Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity

(2008) M. Mraz et al.   CLINICAL ENDOCRINOLOGY

Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans

(2008) X. Zhang et al.   DIABETES

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES

Serum Adipocyte Fatty Acid-Binding Protein Levels Are Associated With Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients

(2008) J. Hyun Koh et al.   DIABETES CARE

Selective Elevation of Adiponectin Production by the Natural Compounds Derived from a Medicinal Herb Alleviates Insulin Resistance and Glucose Intolerance in Obese Mice

(2008) Aimin Xu et al.   ENDOCRINOLOGY

Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury

(2008) Mingyan Zhou et al.   HEPATOLOGY

Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets

(2008) Masato Furuhashi et al.   NATURE REVIEWS DRUG DISCOVERY